Table 7 Clinicopathologic features according to the SDH expression phenotype in breast cancer
Factors | Tumor phenotype | Stroma phenotype | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
SDHA (+)/ SDHB | SDHA (+)/ SDHB | SDHA (−)/ SDHB | SDHA (-)/ SDHB | P | SDHA (+)/ SDHB | SDHA (+)/ SDHB | SDHA (−)/ SDHB | SDHA (−)/ SDHB | P | |
(+) n = 679 (%) | (−) n = 1 (%) | (+) n = 18 (%) | (−) n = 23 (%) | (+) n = 42 (%) | (−) n = 14 (%) | (+) n = 38 (%) | (−) n = 627 (%) | |||
Histologic grade | 0.038 | 0.150 | ||||||||
I/II | 450 (66.3) | 1 (100.0) | 13 (72.2) | 20 (87.0) | 25 (59.5) | 7 (50.0) | 26 (68.4) | 426 (67.9) | ||
III | 229 (33.7) | 0 (0.0) | 5 (27.8) | 3 (13.0) | 17 (40.5) | 7 (50.0) | 12 (31.6) | 201 (32.1) | ||
Tumor stage | 0.495 | 0.640 | ||||||||
T1 | 329 (48.5) | 0 (0.0) | 6 (33.3) | 15 (65.2) | 20 (47.6) | 7 (50.0) | 24 (63.2) | 299 (47.7) | ||
T2/T3 | 350 (51.5) | 1 (100.0) | 12 (66.7) | 8 (34.8) | 22 (52.4) | 7 (50.0) | 14 (36.8) | 328 (52.3) | ||
Nodal stage | 0.491 | 0.314 | ||||||||
N0 | 398 (58.6) | 1 (100.0) | 11 (61.1) | 15 (65.2) | 21 (50.0) | 10 (71.4) | 20 (52.6) | 374 (59.6) | ||
N1/N2/N3 | 281 (41.4) | 0 (0.0) | 7 (38.9) | 8 (34.8) | 21 (50.0) | 4 (28.6) | 18 (47.4) | 253 (40.4) | ||
ER | 0.284 | 0.205 | ||||||||
Negative | 248 (36.5) | 1 (100.0) | 7 (38.9) | 5 (21.7) | 16 (38.1) | 10 (71.4) | 14 (36.8) | 221 (35.2) | ||
Positive | 431 (63.5) | 0 (0.0) | 11 (61.1) | 18 (78.3) | 26 (61.9) | 4 (28.6) | 24 (63.2) | 406 (64.8) | ||
PR | 0.793 | 0.336 | ||||||||
Negative | 324 (47.7) | 1 (100.0) | 11 (61.1) | 10 (43.5) | 21 (50.0) | 11 (78.6) | 17 (44.7) | 297 (47.4) | ||
Positive | 355 (52.3) | 0 (0.0) | 7 (38.9) | 13 (56.5) | 21 (50.0) | 3 (21.4) | 21 (55.3) | 330 (52.6) | ||
HER-2 | 0.567 | 0.001 | ||||||||
Negative | 539 (79.4) | 0 (0.0) | 14 (77.8) | 20 (87.0) | 26 (61.9) | 13 (92.9) | 21 (55.3) | 513 (81.8) | ||
Positive | 140 (20.6) | 1 (100.0) | 4 (22.2) | 3 (13.0) | 16 (38.1) | 1 (7.1) | 17 (44.7) | 114 (18.2) | ||
Molecular type | 0.057 | <0.001 | ||||||||
Luminal A | 281 (41.4) | 0 (0.0) | 6 (33.3) | 15 (65.2) | 14 (33.3) | 2 (14.3) | 11 (28.9) | 275 (43.9) | ||
Luminal B | 160 (23.6) | 0 (0.0) | 5 (27.8) | 3 (13.0) | 13 (31.0) | 2 (14.3) | 13 (34.2) | 140 (22.3) | ||
HER-2 | 63 (9.3) | 1 (100.0) | 3 (16.7) | 2 (8.7) | 9 (21.4) | 1 (7.1) | 9 (23.7) | 50 (8.0) | ||
TNBC | 175 (25.8) | 0 (0.0) | 4 (22.2) | 3 (13.0) | 6 (14.3) | 9 (64.3) | 5 (13.2) | 162 (25.8) | ||
Ki-67 LI (%, mean ± SD) | 17.5 ± 18.7 | 8.0 ± 0.0 | 16.8 ± 14.0 | 10.0 ± 10.2 | 0.260 | 17.8 ± 15.3 | 24.3 ± 22.8 | 22.1 ± 19.0 | 16.8 ± 18.4 | 0.161 |
Tumor recurrence | 59 (8.7) | 0 (0.0) | 3 (16.7) | 1 (4.3) | 0.955 | 4 (9.5) | 1 (7.1) | 2 (5.3) | 56 (8.9) | 0.877 |
Patient death | 56 (8.2) | 0 (0.0) | 3 (16.7) | 1 (4.3) | 0.968 | 3 (7.1) | 1 (7.1) | 3 (7.9) | 53 (8.5) | 0.727 |